1. Introduction {#sec23307}
===============

Mucormycosis is a rare opportunistic fungal infection characterized by infarction and necrosis of host tissues that is resulted from invasion of the vasculature by hyphae ([@A10858R1]) The most common clinical presentation of mucormycosis is rhino-orbital-cerebral infection. It can also cause pulmonary, gastrointestinal, cutaneous, renal, and disseminated diseases ([@A10858R2]). Diabetes is the most common risk factor, founded in 36% of all cases, followed by hematologic malignancies (17%), and solid organ or hematopoietic stem cell transplantation (12%) ([@A10858R3]). A systematic literature review of Medline was performed (01/1970-12/2012) including the search terms: Liver cirrhosis, Mucormycosis, amputation, gangrene. Additional manual review of the reference lists of the identified case reports. The medical literature on this subject revealed a small number of cases (n = 17 cases including this case) reported in twelve papers ([@A10858R4]-[@A10858R15]), most with fatal outcome.

2. Case Presentation {#sec23308}
====================

A 25-year-old woman with liver cirrhosis secondary to autoimmune hepatitis diagnosed at a local hospital presented with fatigue, painless jaundice and lower limb swelling for two weeks, there was no evidence of hypertension or protenuria excluding the possibility of pre-eclampsia or eclampsia. There was no history of ascites, spontaneous bacterial peritonitis or hepatic encephathy. Pregnancy was terminated at 27th week at the local hospital. She was on 40 mg of Prednisolone daily for possible autoimmune hepatitis, soon after, she developed steroid induced diabetes. She was referred to our hospital after 6 weeks of the intial presentation with two episodes of hematemesis, tachycardia (heart rate 120) and blood pressure of 84/50. The patient was admitted to ICU and started on octreotide and Piperacillin/Tazobactam. Gastroscopy revealed gastric varices and bleeding was endoscopically controlled. During admission, liver function tests worsened, and transjugular liver biopsy showed established liver cirrhosis with no obvious active pathology. We started tapering the steroids slowly after being on 40 mg for 4 weeks with no improvement of jaundice without evidence of active inflammation on liver biopsy. During admission, she developed painful, erythematous lesion on her right forearm at the IV access area that became necrotic and spread quickly and increased in size over a period of 24 hours. The lesion included the skin and subcutaneous tissue and was flecked with tiny black spots. Vital signs: temp 37.4ºC, BP 128/80 mmHg, pulse 66 /min, RR 20 /min, SaO2 100% on room air.

Chest was clear to auscultation and cardiovascular exam was normal. Abdomen was soft and lax, distended with ascites but no tenderness. Extremities showed mild lower limb edema. Her investigations showed a white cell count 14.24 x 103/mm3 with Neutrophils of 86%, hemoglobin 9.2 g/dl, and platelets of 103000 /mm3 , LFT: total bilirubin 457 umol/L, direct 321, alkaline phosphatase 430U/L, ALT 174U/L, AST 248U/L, gamma GT 227, total protein 51g/L, albumin 18g/L, PT 19.4 and INR was 1.7, PTT 58, renal function test was within normal, fasting glucose 9.8 mmol/L. ESR was 2, Blood culture showed no growth after 5 days.

MRI of the right upper extremity showed inflammatory changes through the anterior compartment of the forearm suggestive of fasciitis.

She was taken to the operating room for debridement after 24 hours, delay was due to anesthesia issues in this high risk patients. At this point after 18 days of admission, Prednisolone dose reached 20 mg daily and antibiotic changed from Piperacillin/Tazobactam to Imipenem when the culture results from tissue biopsy grew Klebsiella Pneumonia extended spectrum b lactamase producer (ESBL).

Histopathological examination of the debrided soft tissue revealed necrotic subcutaneous fat and skeletal muscle fibers invaded by broad hyphae, irregularly branched, with rare septations suggestive of mucormycosis ([Figure 1A](#fig5252){ref-type="fig"} and [1B](#fig5252){ref-type="fig"}). There were no clinical symptoms or signs of visceral dissemination of infection to warrant further imaging or biopsy. The patient started on Amphotericin B (Abelcet®) 300mg IV OD after 20 days of admission and was continued on imipenem. In spite of surgical debridement, her condition continued to deteriorate and ended up after 6 days with above elbow amputation, tissue-cultures for both bacteria and fungi were negative. Amphotericin B was stopped after amputation as it was considered that the source of infection was eliminated but was restarted again 3 days after discontinuation with imipenem continued all through with the addition of vancomycin. The patient continued to deteriorate and the stump showed signs of disseminated infection, which proved to be invasive mucormycosis infection. Right shoulder disarticulation done but she passed away 2 days later due to multi-organ failure after 35 days in the hospital.

![A) Extensive fat necrosis from soft tissue of forearm with neutrophilic infiltrate and several irregular broad fungal hyphae. (PAS stain x200) B) Irregular thick fungal hyphae with rare septa invading the walls of blood vessels, a feature of mucor fungal infection. (PAS stain x400)](hepatmon-13-08-10858-g001){#fig5252}

3. Discussion {#sec23309}
=============

There are more than 900 cases of mucormycosis reported in the literature ([@A10858R3]), Diabetes is the most common risk factor but it has been described with hematological malignancy, solid tumors, bone marrow and solid organ transplantation and recipients of deferoxamine therapy ([@A10858R3]). Sixteen cases of mucormycosis are reported in patients with liver cirrhosis ([@A10858R4]-[@A10858R15]). The majority of these cases are rhino-orbital. Three cases including this case were upper extremity and one case was gastric involvement ([Table 1](#tbl6395){ref-type="table"}).

###### All the Cases of Mucormycosis Patients With Liver Cirrhosis and Their Outcomes

  Patients no   Age/ Gender   Child Pugh class   Etiology                               Cirrhosis                                                                         Comorbidity Complication                      Involved Area                                                                                              Treatment                                                              Outcome   Reference        Year
  ------------- ------------- ------------------ -------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- --------- ---------------- ------
  **1**         44/Female     B                  NR [a](#fn4296){ref-type="table-fn"}   NR                                                                                LC[a](#fn4296){ref-type="table-fn"}           Ethmoid sinus, orbit                                                                                       None                                                                   Died      ([@A10858R9])    1993
  **2**         53/Male       B                  HCV[a](#fn4296){ref-type="table-fn"}   HCC[a](#fn4296){ref-type="table-fn"}                                              LC, DM[a](#fn4296){ref-type="table-fn"}       Not done                                                                                                   None                                                                   Died      ([@A10858R10])   1998
  **3**         58/F          C                  NR                                     NR                                                                                LC, DM, RI[a](#fn4296){ref-type="table-fn"}   Paranasal sinuses, orbit, cerebral                                                                         Liposomal AmB[a](#fn4296){ref-type="table-fn"}                         Died      ([@A10858R7])    2003
  **4**         39/M          B                  HCV                                    None                                                                              LC, DM                                        Maxillary, ethmoid & sphenoid sinus,cerebral                                                               Surgery/AmB                                                            Died      ([@A10858R4])    2007
  **5**         57/M          C                  HCV                                    PSE[a](#fn4296){ref-type="table-fn"}, SBP[a](#fn4296){ref-type="table-fn"}, HCC   LC                                            Not done                                                                                                   AmB                                                                    Died      ([@A10858R4])    2007
  **6**         55/M          C                  HBV                                    PSE, SBP, HRS HCC[a](#fn4296){ref-type="table-fn"}                                LC                                            Maxillary, and ethmoid sinus                                                                               None                                                                   Died      ([@A10858R4])    2007
  **7**         15/F          C                  AIH                                    PSE, SBP                                                                          LC, DM, steroid therapy                       Maxillary sinus                                                                                            None                                                                   Died      ([@A10858R4])    2007
  **8**         53/M          C                  HCV                                    None                                                                              LC, DM                                        Maxillary, ethmoid and sphenoid sinuses, orbit, cerebral                                                   Surgery (Orbit enucleation & endoscopic debridement of sinuses)/ AmB   Died      ([@A10858R4])    2007
  **9**         35/M          C                  HCV                                    SBP, HRS                                                                          LC, DM                                        Maxillary ethmoid and sphenoid sinus, orbit                                                                AmB                                                                    Died      ([@A10858R4])    2007
  **10**        63/F          B                  HCV                                    None                                                                              LC                                            Maxillary, ethmoid sphenoid sinuses and orbit                                                              Surgery/AmB, Liposomal AmB                                             Alive     ([@A10858R12])   2009
  **11**        42/M          C                  HBV                                    PSE                                                                               None                                          Sphenoid, ethmoid, and maxillary sinuses                                                                   AmB                                                                    Died      ([@A10858R5])    2010
  **12**        59/F          C                  Alcohol                                PSE                                                                               LC, HTN                                       Paranasal sinuses, orbits, bilateral infratemporal fossa, right cavernous sinuses, bilateral optic nerve                                                                          Died      ([@A10858R6])    2011
  **13**        65/M          B                  HCV                                    None                                                                              DM, HTN                                       Maxillary and ethmoid sinuses                                                                              Surgery, AmB, liposomal AmB, itraconazole, posaconazole                Alive     ([@A10858R11])   2012
  **14**        47/M          C                  HCV                                    Gastric mucormycosis, Cirrhosis                                                   HTN, DM                                       Gastric Ulcer                                                                                              Amphotericin B                                                         Died      ([@A10858R14])   2012
  **15**        38/F          C                  Alcohol                                PSE, SBP, HRS                                                                     LC, steroids                                  Right Forearm                                                                                              Amputation                                                             Died      ([@A10858R13])   2007
  **16**        48/F          NR                 Alcohol                                PSE                                                                               NR                                            Right Forearm                                                                                              Local excision                                                         Died      ([@A10858R15])   2010
  **17**        25/F          C                  AIH                                    Variceal bleeding                                                                 LC, steroids                                  Right Forearm                                                                                              Amputation, AmB                                                        Died      This case        2013

^a^Abbreviations: AmB, amphotericin B; DM, diabetes mellitus; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HCC, hepatocellular carcinoma; HTN, hypertension; PSE, portosystemic encephalopathy; SBP, spontaneous bacterial peritonitis; HRS, hepatorenal syndrome; LC, liver cirrhosis; RI, renal insufficiency; NR, Not reported

To our knowledge, there are only two cases of upper limb mucormycosis which are reported previously in association with cirrhosis ([@A10858R13], [@A10858R15]). Moreover, cases of limb involvement in the post-transplant setting are rare ([@A10858R16]). Raizman et al., reported in 2007 the first case of upper extremity mucormycosis in the setting of liver cirrhosis in a 38 year old lady with alcoholic cirrhosis, who was on steroids. She developed gangrene and underwent amputation. The diagnosis was confirmed after the patient death ([@A10858R13]). Wollstein et al, reported another case in 2010 of a 48 year old lady with decompensated alcoholic cirrhosis and hepatic encephalopathy admitted with pneumonia and septic shock, developed of right forearm mucormycosis treated with local excision, and eventually she died ([@A10858R15]). In our case, the diagnosis was made relatively early and the patient was started on antifungal therapy few days after the initial presentation. As in the case reported in 2007, our patient died despite above elbow amputation followed by shoulder disarticulation together with antifungal therapy. There was an initial insult to the forearm with an IV access in our case. In some cases a traumatic incident preceded the infection. In a case described by Raizman et al., the infection seemed to have started in an arterial line and caused necrosis of the hand distally ([@A10858R13]). Another case of localized mucormycosis was described following an intramuscular injection of corticosteroids ([@A10858R17]). Another case was reported after use of contaminated dressing ([@A10858R18]).

Mucormycosis in liver cirrhosis has been reported, including the present case, in 17 patients: 9 males and 8 females. Cirrhosis was due to HCV in 8 patients; HBV in 2; autoimmune hepatitis (AIH) in 2; and alcoholic liver disease (ALD) in 3. The etiology was not reported in 2 cases. Mucormycosis was not reported in Child A, there were 11 cases with Child C and 5 with Child B and in one case, the Child's score was not reported ([@A10858R15]). The two survivals of mucormycosis in patients with liver cirrhosis were in patients with Child' B cirrhosis ([@A10858R11], [@A10858R12]). Eight cases have DM as co-morbidity while 3 patients were on steroids.

The mortality is high despite aggressive surgical debridement and proper antifungal and antibacterial coverage, there was a relative delay in diagnosing the fungal infection but treatment started once the cultures came back positive. The outcome may be determined mainly by underlying risk factor; mucormycosis in diabetics has 60% to 90% the survival, where it is 20%-50% in Leukemia. In Cirrhosis it is 11.7% (2 out of 17 patients).

In conclusion; mucormycosis carries high mortality in patients with liver cirrhosis despite aggressive treatment, the three cases with limb involvement, the gastric mucromycosis and 11 out of 13 cases of rhino-orbital involvement died. From this case and in reviewing the literature, it seems that underlying risk factors of the patient determine the final outcome more than the particular treatment provided.
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**Implication for health policy/practice/research/medical education:**

This paper is a case report with review of the literature collecting all cases of mucormycosis in patients with liver cirrhosis, the message this paper is conveying is that even though mucormycosis is rare in the setting of cirrhosis, but it carries a very high mortality compared with mucormycosis in the setting of diabetes or hematological malignancies. This will be of an interest to the general and transplant hepatologist.
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